# OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

> **NCT02097121** · PHASE3 · TERMINATED · sponsor: **Allergan** · enrollment: 56 (actual)

## Conditions studied

- Urinary Incontinence
- Urinary Bladder
- Overactive

## Interventions

- **BIOLOGICAL:** BOTOX®

## Key facts

- **NCT ID:** NCT02097121
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-23
- **Primary completion:** 2022-02-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097121, "OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02097121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*